1. Nuvation Bio & Eisai's Taletrectinib NSCLC Therapy Advances with EMA Application Acceptance
The European Medicines Agency (EMA) has accepted the marketing authorization application for taletrectinib, a targeted therapy for non-small cell lung cancer (NSCLC) developed by Nuvation Bio and Eisai. This regulatory milestone signals a critical step forward for the drug's potential entry into the European market, pl...